2. Academic Validation
  3. A Non-Metallic Nanozyme Ameliorates Pulmonary Hypertension Through Inhibiting ROS/TGF-β1 Signaling

A Non-Metallic Nanozyme Ameliorates Pulmonary Hypertension Through Inhibiting ROS/TGF-β1 Signaling

  • Adv Healthc Mater. 2024 Aug 18:e2401909. doi: 10.1002/adhm.202401909.
Ruxia Liu 1,  Ting Zhou 2 3,  Xinsheng Li 2,  Quan Zou 4 5,  Jiaojiao Yu 2,  Jingjing Ye 6,  Wenhui Wang 7,  Yan Zhou 8,  Shao-Kai Sun 2
Affiliations

Affiliations

  • 1 Department of Rehabilitation, School of Medical Technology, Tianjin Medical University, Tianjin, 300203, China.
  • 2 School of Medical Imaging, Tianjin Medical University, Tianjin, 300203, China.
  • 3 Department of CT, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi Province, 710068, China.
  • 4 School of Medical Imaging, Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University, Tianjin, 300203, China.
  • 5 Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
  • 6 Trauma Treatment Center, Peking University People's Hospital, Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education, National Center for Trauma Medicine, Beijing, 100044, China.
  • 7 Department of Endocrinology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
  • 8 Department of Ultrasound, Tianjin Third Central Hospital, Tianjin, 300170, China.
PMID: 39155419 DOI: 10.1002/adhm.202401909
Abstract

Pulmonary hypertension (PH) is a life-threatening Cardiovascular Disease with a lack of effective treatment options. Nanozymes, though promising for PH therapy, pose safety risks due to their metallic nature. Here, a non-metallic nanozyme is reported for the treatment of monocrotaline (MCT)-induced PH with a therapeutic mechanism involving the ROS/TGF-β1 signaling. The synthesized melanin-polyvinylpyrrolidone-polyethylene glycol (MPP) nanoparticles showcase ultra-small size, excellent water solubility, high biocompatibility, and remarkable antioxidant capacity. The MPP nanoparticles are capable of effectively eliminating ROS in isolated pulmonary artery smooth muscle cells (PASMCs) from PH rats, and significantly reduce PASMC proliferation and migration. In vivo results from a PH model demonstrate that MPP nanoparticles significantly increase pulmonary artery acceleration time, decrease wall thickening and PCNA expression in lung tissues, as evidenced by echocardiograpy, histology and immunoblot analysis. Additionally, MPP nanoparticles treatment improve running capacity, decrease Fulton index, and attenuate right ventricular fibrosis in MCT-PH rats by using treadmill test, picrosirius red, and trichrome Masson staining. Further transcriptomic and biochemical analyses reveal that inhibiting ROS-driven activation of TGF-β1 in the PA is the mechanism by which MPP nanoparticles exert their therapeutic effect. This study provides a novel approach for treating PH with non-metallic nanozymes based on a well-understood mechanism.

Keywords

ROS; TGF‐β1 signaling; melanin; non‐metallic nanozyme; pulmonary hypertension.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z